Jul 2nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Meitheal Pharmaceuticals has obtained exclusive U.S. commercial rights for YUSIMRY, a biosimilar to Humira.

The U.S. Food and Drug Administration (FDA) approved inebilizumab on June 11, 2020.

CASI Pharmaceuticals Plans IND Submission for CID-103 in Antibody-Mediated Rejection and Receives Non-Binding Offer to Acquire Its China Operations.

The U.S. Food and Drug Administration (FDA) approved Oriahnn on May 29, 2020.

The U.S. FDA has granted approval to EPKINLY® (epcoritamab-bysp) for individuals with relapse or refractory (R/R) follicular lymphoma (FL).

The U.S. Food and Drug Administration (FDA) approved Tauvid on May 28, 2020.

Lyell Immunopharma Announces Phase 1 Results for ROR1-targeted CAR-T Candidate, LYL797, Showing Dose-dependent Efficacy Enhanced by Anti-exhaustion Technology.

The U.S. Food and Drug Administration (FDA) approved Phexxi on May 22, 2020.

Simcere Zaiming, announced that their new anti-EGFR antibody treatment, Enlituo®, has been officially approved for sale by the China National Medical Administration.

Cerianna (fluoroestradiol F 18) is FDA approved. The U.S. Food and Drug Administration (FDA) approved Cerianna on May 20, 2020.

6.24-6.30 Global Drug R&D Progress & Pharmaceutical Transaction Trends.